STUDYING THE EFFECT OF CV247 COMPONENT IN HUMAN ESTABLISHED CANCER CELL LINES BECOMING FROM PROSTATE AND BREAST CARCINOMAS.

M. Toloudi¹, P. Apostolou¹, M. Chatzioannou¹, I. Papasotiriou¹,²
¹ R.G.C.C. Ltd. (Research Genetic Cancer Centre Ltd.), Filotas, Florina
² Martin-Luther-Universität Halle-Wittenberg, Onkologie-Hämatologie Abteilung, Halle (Saale), Deutschland

INTRODUCTION
CV247 is a combination of already known substances such as gluconate manganese, gluconate copper, sodium salycylate as well as ascorbic acid (vitamin C). The scientific community has proven its great impact to many types of malignancies, as it reduces the proliferation rate of cancer cells and as a result the tumor mass. Additionally, it has been proven that it has improved the standard of living of many patients with advanced stage of prostate cancer. Having in mind the synergistic effect of its components as well as the properties of its substance separately, this study aims to prove the hypothesis that CV247 agent inhibits and/or inactivates the molecular pathways of cancer development.

MATERIALS
Human established cancer cell lines which were obtained form the European Collection of Cell Cultures (ECACC), were used in order to prove the effect of CV247. The human cancer cell lines represented breast carcinomas (MDA-MB 231, MFM-223 and T47D) as well as prostate carcinomas (PC3, 22Rv1 and LNCaP).

METHODS
The panel of the experiments includes assays which are based on the quantification analysis of living cells by using indirect parameters (chemosensitivity – colorimetric assays) such as MTT (methyl tetrazolium dye), SRB (Sulforhodamine B assay) and CVE (Crystal Violet dye) in different incubation periods (0h, 24h & 48h) and concentrations of the drug (1/100 & 1/200).

RESULTS
The results indicate that CV247 has a greater effect in breast tumors as it reduces the number of living breast cancer cells more that the prostate cancer cells. The figures below indicate the CV247’s action in MDA-MB 231 cell line.

CONCLUSION
This is one of the most significant studies that proves the cytotoxic/cytostatic impact of CV247 agent primarily in breast than in prostate carcinomas.

Table 1. Decrease fold of the cells which were incubated with CV247 when compared with untreated cells. The percentage is almost 50%.

<table>
<thead>
<tr>
<th></th>
<th>CVE FOLD DECREASE</th>
<th>SRB FOLD DECREASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1/100</td>
<td>1/200</td>
</tr>
<tr>
<td>0h</td>
<td>-5.2</td>
<td>-8.2</td>
</tr>
<tr>
<td>24h</td>
<td>25.2</td>
<td>-0.9</td>
</tr>
<tr>
<td>48h</td>
<td>40.7</td>
<td>37.8</td>
</tr>
</tbody>
</table>

References
- www.ivymedical.com/history-product.html